ORIC Pharmaceuticals registers Phase 3 Himalayas-1 trial for rinzimetostat in mCRPC

This week's item is a newly listed Phase 3 trial from ORIC Pharmaceuticals.

• The trial, titled "Himalayas-1" (NCT07723248), is a randomized, open-label Phase 3 study sponsored by ORIC Pharmaceuticals with Bayer as collaborator, and was first posted on 2026-07-23. It tests rinzimetostat combined with darolutamide against physician's choice of an androgen receptor pathway inhibitor (darolutamide or enzalutamide) or docetaxel in metastatic castration resistant prostate cancer patients who had previously received abiraterone acetate¹. The study's main goal is showing superior radiographic progression free survival for the rinzimetostat plus darolutamide arm compared with the control arm¹. The record lists an estimated enrollment of 600 participants¹, with recruiting status and an actual start date of 2026-08-03, and estimated primary completion in 2028-03.